Avidity Biosciences (NASDAQ:RNA) Insider Teresa Mccarthy Sells 1,965 Shares

January 10, 2026 by InsiderTrades.com

Key Points

CEO Sarah Boyce sold 8,576 shares on Jan. 7 at an average price of $72.23 for about $619,444, reducing her holdings to 283,394 shares (a 2.94% decrease).
Avidity trades near its one‑year high (~$72.61) with a market cap of ~$10.9B; the company reported a quarterly EPS loss of ($1.27) that missed estimates while revenue jumped 420.8% to $12.48M, and analysts have a consensus "Hold" with an average price target of $69.57.

Avidity Biosciences, Inc. (NASDAQ:RNA - Get Free Report) insider Teresa Mccarthy sold 1,965 shares of the stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $72.23, for a total value of $141,931.95. Following the transaction, the insider owned 116,867 shares of the company's stock, valued at $8,441,303.41. This represents a 1.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

This Early-Stage Biotech Stock Is Up 400% — Should You Buy Now?

Teresa Mccarthy also recently made the following trade(s):

On Wednesday, October 15th, Teresa Mccarthy sold 20,000 shares of Avidity Biosciences stock. The shares were sold at an average price of $50.15, for a total transaction of $1,003,000.00.

Avidity Biosciences Price Performance

RNA stock opened at $72.37 on Friday. The company has a fifty day simple moving average of $71.41 and a two-hundred day simple moving average of $52.73. Avidity Biosciences, Inc. has a 52 week low of $21.51 and a 52 week high of $72.61. The firm has a market capitalization of $10.90 billion, a P/E ratio of -17.31 and a beta of 0.95.

Avidity Biosciences (NASDAQ:RNA - Get Free Report) last announced its quarterly earnings results on Monday, November 10th. The biotechnology company reported ($1.27) EPS for the quarter, missing analysts' consensus estimates of ($1.05) by ($0.22). Avidity Biosciences had a negative net margin of 2,634.59% and a negative return on equity of 37.70%. The business had revenue of $12.48 million during the quarter, compared to the consensus estimate of $1.80 million. The firm's revenue for the quarter was up 420.8% on a year-over-year basis. As a group, analysts anticipate that Avidity Biosciences, Inc. will post -2.89 EPS for the current year.

Institutional Investors Weigh In On Avidity Biosciences

Several hedge funds have recently made changes to their positions in RNA. AlphaQuest LLC grew its position in shares of Avidity Biosciences by 123.0% during the 3rd quarter. AlphaQuest LLC now owns 600 shares of the biotechnology company's stock worth $26,000 after buying an additional 331 shares in the last quarter. CWM LLC lifted its stake in Avidity Biosciences by 1,635.1% in the third quarter. CWM LLC now owns 642 shares of the biotechnology company's stock worth $28,000 after acquiring an additional 605 shares during the period. Westside Investment Management Inc. bought a new position in Avidity Biosciences during the 2nd quarter worth about $29,000. Allworth Financial LP increased its position in Avidity Biosciences by 22.8% during the 3rd quarter. Allworth Financial LP now owns 856 shares of the biotechnology company's stock valued at $37,000 after purchasing an additional 159 shares during the period. Finally, PNC Financial Services Group Inc. raised its holdings in shares of Avidity Biosciences by 291.5% in the 2nd quarter. PNC Financial Services Group Inc. now owns 1,476 shares of the biotechnology company's stock valued at $42,000 after purchasing an additional 1,099 shares in the last quarter.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on RNA shares. Weiss Ratings reissued a "sell (d-)" rating on shares of Avidity Biosciences in a research note on Wednesday, October 8th. Wolfe Research downgraded shares of Avidity Biosciences from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, October 28th. Evercore ISI set a $72.00 target price on Avidity Biosciences in a research report on Thursday, December 18th. Wall Street Zen upgraded Avidity Biosciences from a "sell" rating to a "hold" rating in a report on Saturday, October 25th. Finally, Citigroup cut Avidity Biosciences from a "buy" rating to a "hold" rating in a report on Monday, October 27th. Eight research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Avidity Biosciences has a consensus rating of "Hold" and a consensus target price of $69.57.

Get Our Latest Stock Report on Avidity Biosciences

Avidity Biosciences News Roundup

Here are the key news stories impacting Avidity Biosciences this week:

Neutral Sentiment: W. Michael Flanagan sold 2,373 shares (~$171.4k), reducing his stake ~2.52%. SEC filing - Flanagan sale
Neutral Sentiment: Michael F. Maclean (CFO) sold 1,974 shares (~$142.6k), a ~3.00% decrease in his ownership. SEC filing - Maclean sale
Neutral Sentiment: Teresa McCarthy sold 1,965 shares (~$141.9k), reducing her stake ~1.65%. SEC filing - McCarthy sale
Negative Sentiment: Steven George Hughes sold 2,373 shares (~$171.4k), a ~6.11% reduction in his position — larger proportional sale that may draw investor scrutiny. SEC filing - Hughes sale
Negative Sentiment: John B. Moriarty sold 2,374 shares (~$171.5k), a ~3.09% drop in his holdings. SEC filing - Moriarty sale
Negative Sentiment: Charles Calderaro III sold 3,727 shares (~$269.2k), a ~6.96% reduction — one of the larger proportional sales among insiders. SEC filing - Calderaro sale
Negative Sentiment: CEO Sarah Boyce sold 8,576 shares (~$619.4k), reducing her stake ~2.94%; CEO sales tend to attract investor attention despite modest percentage change. SEC filing - Boyce sale

Avidity Biosciences Company Profile

(Get Free Report)

Avidity Biosciences is a clinical-stage biotechnology company dedicated to developing antibody-oligonucleotide conjugate (AOC) therapies designed to address serious neuromuscular and cardiac diseases. The company's proprietary AOC platform combines the targeting specificity of monoclonal antibodies with the gene-modulating power of oligonucleotides to deliver therapeutic agents directly into muscle cells. Headquartered in La Jolla, California, Avidity seeks to overcome traditional delivery challenges associated with RNA-based medicines by leveraging receptor-mediated uptake mechanisms.

The company's lead product candidate, AOC 1001, is in clinical development for myotonic dystrophy type 1 (DM1) and represents the first application of the AOC platform in a human study.